Premium
Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
Author(s) -
Landau D.,
Tsakok T.,
Aylwin S.,
Hughes S.
Publication year - 2012
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2011.04233.x
Subject(s) - prostate cancer , medicine , testosterone (patch) , testosterone replacement , androgen , androgen deprivation therapy , prostate , oncology , endocrinology , cancer , urology , hormone
Summary Androgen administration can cause prostate cancer progression, and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer. In trying to answer the posed clinical question, this article reviews the risks and benefits of testosterone replacement therapy in this setting and the published data from clinical series. Recommendations are made based on the available evidence.